Trade Report: Today: 38,459 Shares of Stock are sold by Insider Selling: CytomX Therapeutics Inc. (CTMX) Director

Today: 38,459 Shares of Stock are sold by Insider Selling: CytomX Therapeutics Inc. (CTMX) Director

CytomX Therapeutics Inc. (NASDAQ:CTMX) Director Ix L.P. Canaan sold 38,459 shares of the firm’s stock in a transaction dated Monday, November 28th. The stock was sold at an average price of $11.56, for a total value of $444,586.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ix L.P. Canaan also recently made the following trade(s): On Tuesday, November 22nd, Ix L.P. Canaan sold 42,550 shares of CytomX Therapeutics stock. The stock was sold at an average price of $11.71, for a total value of $498,260.50. On Monday, November 21st, Ix L.P. Canaan sold 45,324 shares of CytomX Therapeutics stock. The stock was sold at an average price of $11.61, for a total value of $526,211.64. On Wednesday, November 16th, Ix L.P. Canaan sold 51,581 shares of CytomX Therapeutics stock. The stock was sold at an average price of $11.50, for a total value of $593,181.50. On Monday, November 14th, Ix L.P. Canaan sold 86,270 shares of CytomX Therapeutics stock. The shares were sold at an average price of $11.16, for a total value of $962,773.20. On Wednesday, November 9th, Ix L.P. Canaan sold 13,730 shares of CytomX Therapeutics stock. The shares were sold at an average price of $11.03, for a total value of $151,441.90.

Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) traded down 4.49% during mid-day trading on Monday, hitting $11.28. The stock had a trading volume of 125,650 shares. The stock’s 50-day moving average is $12.13 and its 200 day moving average is $11.68. CytomX Therapeutics Inc. has a 12 month low of $9.10 and a 12 month high of $24.68. The company’s market cap is $410.61 million.

Separately, Zacks Investment Research upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Tuesday, November 8th.

A number of hedge funds have recently bought and sold shares of CTMX. BlackRock Advisors LLC boosted its stake in CytomX Therapeutics by 21,170.0% in the second quarter. BlackRock Advisors LLC now owns 542,384 shares of the company’s stock worth $5,541,000 after buying an additional 539,834 shares during the period. Tekla Capital Management LLC boosted its stake in CytomX Therapeutics by 130.5% in the second quarter. Tekla Capital Management LLC now owns 756,090 shares of the company’s stock worth $7,723,000 after buying an additional 428,031 shares during the period. BlackRock Fund Advisors boosted its stake in CytomX Therapeutics by 168.6% in the second quarter. BlackRock Fund Advisors now owns 527,248 shares of the company’s stock worth $5,386,000 after buying an additional 330,966 shares during the period. Private Advisor Group LLC purchased a new stake in CytomX Therapeutics during the second quarter worth approximately $2,232,000. Finally, State Street Corp boosted its stake in CytomX Therapeutics by 177.3% in the second quarter. State Street Corp now owns 254,501 shares of the company’s stock worth $2,599,000 after buying an additional 162,724 shares during the period. Institutional investors own 54.19% of the company’s stock.

About CytomX Therapeutics

Related posts

Leave a Comment